PTH and Paget disease: In 2015 FDA and in 2017 EMA approved the use of PTH intact analog (1–84) for the treatment of hypoPTH not controlled by conventional therapy, in the absence of contraindications (hypersensitivity to the active substance or to one of the excipients, ongoing or previous skeletal radiotherapy, malignant neoplasms of the skeleton or bone metastases, patients with increased risk of osteosarcoma, such as patients with Paget disease or with genetic bone diseases, patients with unexplained increase in bone alkaline phosphatase).